Susanna High
Equibles does not estimate personal net worth.
About Susanna High
Earlier roles on record: COO at Dyne Therapeutics, Inc. (DYN) until October 1, 2024. Dyne Therapeutics, Inc. reported in an 8-K filed September 3, 2024 that Susanna High resigned as Chief Operating Officer, effective October 1, 2024. The proxy statement of Dyne Therapeutics, Inc. reports total compensation of $2,045,442 for Susanna High in fiscal 2023, including a base salary of $497,888. Disclosed compensation is on record for 4 fiscal years.
“Dr. McNeill’s resignation is effective September 3, 2024, and Ms. High’s resignation is effective October 1, 2024.”
Affiliation history
-
Start not stated–2024-10-01
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Dyne Therapeutics, Inc. (DYN) | Chief Operating Officer | $497,888 | $2,045,442 |
| 2022 | Dyne Therapeutics, Inc. (DYN) | Chief Operating Officer | $467,500 | $1,594,292 |
| 2021 | Dyne Therapeutics, Inc. (DYN) | Chief Operating Officer | $425,000 | $1,690,621 |
| 2020 | Dyne Therapeutics, Inc. (DYN) | Chief Operating Officer | $167,788 | $3,745,915 |